Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503265 · ClinicalTrials.gov registry record · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by AtlasMedx, Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 4
- Study locations
NCT04503265 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by AtlasMedx, Incorporated. The registered enrollment target is 122 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04503265, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by AtlasMedx, Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 4
- Study locations
Study Summary
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Conditions Studied
Interventions
- DRUG AMXI-5001:Dose Escalation Phase I
- DRUG AMXI-5001:Dose Expansion Phase II
Study Locations (4)
California
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology - Los Angeles
Maryland
- Johns Hopkins - Baltimore
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04503265
The ClinicalTrials.gov registry entry for NCT04503265 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is AtlasMedx, Incorporated, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which AMXI-5001:Dose Escalation Phase I is the first listed.
NCT04503265 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04503265 about?
NCT04503265 is a clinical study titled "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies". ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to chara...
What is the current status of trial NCT04503265?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2020-08-12. Estimated completion is 2026-10.
What conditions does trial NCT04503265 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Advanced Malignant Neoplasm.
What interventions are being tested in trial NCT04503265?
The interventions under investigation include: AMXI-5001:Dose Escalation Phase I (DRUG), AMXI-5001:Dose Expansion Phase II (DRUG).
Who is sponsoring clinical trial NCT04503265?
This trial is sponsored by AtlasMedx, Incorporated, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04503265 being conducted?
This trial has 4 study locations across California, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.